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Background
Alzheimer’s disease (AD) is a neurodegenerative disorder that affects 5.4 million 
people and is the 6th leading cause of death in the United States alone. It is a form 
of dementia that worsens over time until a person can no longer have a conversation 
or respond to environmental stimuli. The major constituents of this disease are senile 
plaques and tangles that result in the death and damage of nerve cells through oxida-
tive stress (Association 2012). Understanding the interaction between acetyl cholinest-
erase (AChE) and small molecules such as drugs which can inhibit this protein are also 
equally important to develop the therapeutic strategies against AD (McGleenon et al. 
1999; Rees and Brimijoin 2003). Small drug molecules were successful to inhibit the 
acetyl cholinesterase (AChE) due to the presence of catalytic triad and aromatic gorge. 
These two most important binding sites are frequently targeted by AChE inhibitor 
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drugs. The active catalytic triad, located near (~ 20 Å) the bottom of a deep and nar-
row gorge, consists of Ser200, His440 and Glu327 (Sussman et  al. 1991). Aromatic 
gorge region which includes 14 aromatic amino acids such as Phe120, Phe288, Phe290, 
Phe330, Phe331, Trp84, Trp233, Trp279, Trp432, Tyr70, Tyr121, Tyr130, Tyr334, and 
Tyr442 and represents the 60  % of its total surface area (Xu et  al. 2008). Similar to 
other protein, these aromatic amino acids are highly conserved. Among these aromatic 
amino acids, some process very distinctive functional activities. For instance, Trp84 
and Phe330 are known as ‘‘anionic’’ subsite of the catalytic site (CAS) involves in cho-
line recognition through cation‒pi interaction whereas Trp279 and Tyr70 contribute 
to the peripheral anionic site (PAS) (Gilson et al. 1994). Trp233, Phe288, Phe290 and 
Phe331 residues along with Gly119 also formed the acyl pocket involves in acetyl ester 
specificity (Harel et al. 1993, 1995).
Currently four drugs are marketed under different brands but are of limited or no 
benefits—three are acetyl cholinesterase inhibitors (rivastigmine, galantamine and 
donepezil) and the other (memantine) is an NMDA receptor antagonist (Birks and Har-
vey 2006; Pohanka 2011). These drugs normally have C-6 or C-5 ring based molecu-
lar structures with functional groups on the side chain. These are thought to prevent 
plaque formation and/or revert the mis-folding of the A-beta protein to its native 3-D 
structure. However, no drugs were found to significantly affect the symptoms or stop the 
progression of the disease in any clinical study. In recent years, significant research has 
been conducted to improve or discover new effective drugs using molecular modeling 
approach and laboratory extraction of natural products or modifying the currently avail-
able one (de Paula et al. 2007, 2009; Haviv et al. 2007; Nascimento et al. 2008; Sugimoto 
et al. 2002). For example, Farrokhnia and Nabipour reported acetyl cholinesterase inhib-
itors extracted from sea hare Aplysiadactylomela and studied their cholinergic actions 
by using molecular docking and density functional theory computations (Farrokhnia 
and Nabipour 2014). Camps et al. (2008) and Alonso et al. (2005) synthesized a series 
of donepezil-tacrine dimeric systems and tested their performance against Acetyl- and 
Butyrylcholinesterase.
Halogenation holds the promise of effective drug design by facilitating the drug mol-
ecules to cross biological barriers, filling small hydrophobic pockets present in protein 
targets, prolonging lifetime and easy adsorption. Being a strong electron-withdrawing 
group, halogens help in forming H‒bond and other non-covalent interactions (Lu et al. 
2009, 2012; Politzer et al. 2007; Sarwar and Ajami 2013; Wilcken et al. 2012). Comparing 
with other halogenations, fluorination and carbon trifluoro-methylation have significant 
contributions to medicinal chemistry (Alonso et  al. 2005; Gillis et  al. 2015; Hagmann 
2008; Zhou et  al. 2009). Halogens stabilize the interactions of drug molecules with 
their protein target by promoting stronger bonding between functional groups through 
charge distribution. Further, some halogens such as I and Br contain regions with posi-
tively charge on them, which is responsible for its directional and stabilizing characteris-
tics on the drug molecules (Kolář et al. 2013).
In this manuscript, we employ density functional theory to design some halogen-
ated donepezil drugs. Earlier it was reported donepezil to show its antagonist activities 
against AChE while the piperidine ring being at chair conformation (Kryger et al. 1999). 
Here we have considered both the chair and the boat conformation of the piperidine 
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ring prior to modifying the parent drug. Moreover, with the aid of molecular docking 
calculation, we report their interaction with different binding sites of AChE. These halo-
genated drugs show a considerable improvement in bonding with the target based on 




All calculations were carried out using Gaussian 09 program package (Frisch et al. 2009). 
Initial three-dimensional geometry of chair forms of donepezil was retrieved from the 
bound crystal structure of 1EVE (Berman et  al. 2002). The parent drug was modified 
with F, Cl, Br, I and –CF3 functional groups. These structures were fully optimized by 
density functional theory employing Becke’s exchange functional combining Lee, Yang, 
and Parr’s (LYP) correlation functional (Becke 1988; Lee et al. 1988). Midix basis set was 
employed for –Cl, –Br and –I substituted ligands, while 6-311G +  (d,p) basis set was 
used for the parent drug and the –F and –CF3 modified derivatives (Easton et al. 1996). 
MidiX basis set is originally developed from the Huzinaga MidiX basis and applied to 
H, C–F, S–Cl, Br, and I atoms and can provide excellent geometries and charge balances 
with reasonable computational time and accuracy (Li et  al. 1998). After optimization, 
subsequent vibrational frequency calculation has been performed to confirm that the 
stationary points correspond to minima on the Potential Energy Surface. Electronic 
energies, enthalpy, Gibbs free energies, and dipole moments and partial charge analysis 
of each compound were also investigated.
To predict the chemical reactivity descriptor of all ligands, molecular orbital calcula-
tions were performed at same level of theory. Hardness and softness of all drugs were 
also calculated from the energies of frontier HOMOs and LUMOs. Hardness (η) and 
softness (S) of the drugs calculated according to the following equation (Pearson 1986, 
1995)
Preparation of protein
The halogenated donepezil were subjected to molecular docking study against acetyl 
cholinesterase (AChE). Crystal structur of AChE were collected from the Protein Data 
Bank (PDB) database (PDB ID: 1EVE) (Berman et al. 2002). Prior to docking, water mol-
ecules were removed from the crystal structure followed by the addition of non-polar 
hydrogen atoms using AutoDock Tools (ADT) of MGL software packages (version 1.5.6). 
Later on, the fully optimized structures of the halogenated compounds were opened 
using ADT to add gasteiger charges and to set TORSDOF followed by the conversion of 
all rotatable bonds into non-rotatable. Next, we saved both the protein and ligand struc-
tures in .PDBQT format as it is the only one supported file format that required by Auto-
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Binding site and docking
The active binding pocket of AChE is predicted by CASTp—having the highest pocket 
area and volume are 763.5  Å2 and 1716.4  Å3, respectively (Dundas et  al. 2006). The 
binding pocket and the amino acid residues are presented in Additional file  1: Figure 
S1 (supporting information). These residues have been identified to contribute to the 
structural and functional properties of the protein by catalytic tirade and most of the 
aromatic gorge. The binding site residues predicted by CastP for AChE were used for 
grid generation.
While docking ligands against AChE, center grid box was set at 65.2551, 63.0417 
and 59.0772 Å. Autodock Vina docking protocol was employed to conduct the dock-
ing study. The docked pose of lowest binding free energy conformer with the respective 
protein was analyzed using PyMOL Molecular Graphics System (version 1.7.4) (DeLano 
2002), Accelrys Discovery Studio 4.1 (“Accelrys Software Inc., Discovery Studio Mod-
eling Environment, Release 4.0, San Diego: Accelrys Software Inc.,” 2013).
Pharmacokinetic parameters study
We have utilized AdmetSAR online database to evaluate the pharmacokinetic param-
eters related to drug absorption, metabolism and toxicity for the parent drug and its 
modifiers (Cheng et al. 2012). Prior to that, SDF (Structure Data File) and SMILES (sim-
plified molecular- input line-entry system) strings were utilized throughout the genera-
tion process.
Result and discussion
Figure 1 shows two dimensional structures of donepezil in both chair and boat forms. 
The optimized structure of donepezil (D) and its halogenated derivatives (D1-D5) at 
chair form are presented in Fig. 2. The stoichiometry, electronic energy, enthalpy, Gibbs 
Fig. 1 Chair and boat conformations of Donepezil
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free energy and dipole moment of the ligands are reported in Table 1. The HOMO and 
LUMO energy values, the energy gap, and softness of all ligands are presented in Table 2. 
The binding affinity and important non-covalent interactions of all ligand–receptor 
complexes are summarized in Tables 3 and 4 respectively.     
Binding affinity of Donepezil (D) and modified drugs (D1–D5) in chair form against AChE
Halogen-directed modifications on donepezil significantly influence the structural prop-
erties of the ligands in terms of energy, partial charge distribution and dipole moment. 
In D1, introducing a fluorine atom at 54 positions replacing the H atom changes the free 
energy to −1303.57 Hartree from −1204.88 Hartree. In D1, the dipole moment increases 
Fig. 2 Optimized structure of Donepezil (D) Chair form and its halogenated derivatives (D1, D2, D3, D4 and 
D5) calculated at B3LYP/MidiX level of theory
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by 1.25 D compared to donepezil. This may play a role in determining the activity of 
ligands as elevated dipole moment has been considered a good indicator to promote 
non‒bonded interactions in drug-receptor complexes (Lien et  al. 1982). F atom inter-
changes the partial charge on C21 to +0.215 a.u. from −0.326 a.u. with a partial charge 
of −0.308 a.u. on F. Inclusion of F kept a role to increasing the softness of D1 (13.27) 
compared to that of the parent ligand D (11.79). The H54–C21 bond distance (1.09 Å) 
increases when H is replaced by F to 1.41 Å. Gibbs free energy of the parent drug went 
towards more negative value when H54 had been replaced by F in D1. Binding affinity 
of D and D1 against AChE was computed as −11.1 and −11.7 kcalmol−1 respectively, 
which demonstrated the fact that inclusion of a high electronegative group affects the 
overall ligand–receptor interaction scenario. Farrokhnia and Nabipour (2014) docked 
donepezil with AChE and found the binding energy value to be −11.2 kcalmol−1 which 
is in good agreement with our computed value. In D-AChE complex, Phe330 in AChE 
Table 1 The stoichiometry, electronic energy, enthalpy, Gibbs free energy in  Hartree 
and dipole moment (Debye) of donepezil chair form and its derivatives
Name Stoichiometry Electronic energy Enthalpy Gibbs free energy Dipole moment
D_Chair C24H29NO3 −1204.887 −1204.887 −1204.970 2.58 
D1_Chair C24H28FNO3 −1303.572 −1303.571 −1303.656 3.82
D2_Chair C24H28ClNO3 −1662.323 −1662.322 −1662.409 4.31
D3_Chair C24H28BrNO3 −3766.304 −3766.303 −3766.390 3.78
D4_Chair C24H28INO3 −8094.427 −8094.427 −8094.515 3.77
D5_Chair C25H28F3NO3 −1540.040 −1540.038 −1540.132 1.64
Table 2 Energy (atomic unit) gaps of  HOMOs, LUMO, Gap, Hardness and  Softness of  all 
drugs
Molecules εHOMO εLUMO Gap S (Softness)
D_Chair −0.21374 −0.04412 0.16962 11.79106
D1_Chair −0.20857 −0.05763 0.15094 13.26787
D2_Chair −0.21086 −0.06102 0.14984 13.34757
D3_Chair −0.21101 −0.06008 0.15093 13.25118
D4_Chair −0.21245 −0.06621 0.14624 13.67614
D5_Chair −0.22074 −0.04579 0.17495 11.43183
Table 3 Free energy of  binding values (Kcalmol−1) for  ligand – AChE (at chair and  boat 
form) systems obtained from flexible docking
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has previously been described by Kryger et al. as a “swinging gate” and its tendency to 
alter conformation has been anticipated to having an important role in the activity of 
the ligand. They also indicated of the presence a pi‒stacking interaction involving the 
phenyl ring at Phe330 (Kryger et al. 1999). In the present work, the pi‒pi interaction at 
Phe330 has been observed with the bond distance being 4.03 Å (Fig. 3). This was how-
ever in contrast with the experimental observation by Kryger et al. where the interaction 
had been at the piperidine nitrogen. A good number of pi‒pi interactions were observed 
that show the bond distance varying between 3.80 Å to as far as 5.00 Å. Some recent 
researches, however, indicated that ideal bond distance in pi‒pi interactions are within 
the range 3.30–4.00 Å (Janiak 2000; Martinez and Iverson 2012; Avasthi et al. 2014). The 
optimized geometry of donepezil was not found to show any contact with the so-called 
catalytic triad consisting three amino acid residues Ser200, His440 and Glu327 as noted 
by Kryger et al. Instead, parent drug D and the modified ligands mostly showed good 
contacts with the aromatic amino acid gorge involving mainly pi‒stacking interactions. 
For example, parent drug D was found to generate stacking contacts with the delocal-
ized electrons at indole fragment of Trp84 and Trp279, the aromatic ring of Phe331 and 
Tyr334. Earlier Trp84 was reckoned as one of the important residues of the active site of 
Table 4 Selected non-covalent interactions among chair ligands D–D5 and AChE obtained 
via flexible docking
Brackets indicate the amino acid residues that are in contact with the ligands
Asp asparatic acid, Gly glycine, Glu glutamine, Phe phenylalanine, Ser serine, Trp tryptophan, Tyr tyrosine
Systems Contacts Bond distances (Å) Systems Contacts Bond distances (Å)
D-AchE C–H···O (Tyr70) 2.66 D3-TYMS C–H···O (Asp72) 2.94
pi···pi (Trp84) 3.85 pi···pi (Trp84) 3.90, 4.01
pi···pi (Trp279) 4.14 pi···pi (Trp279) 4.41, 5.61
O···H–N (Phe288) 2.84 C–H···O (Ser286) 2.81
pi···pi (Phe330) 4.03 C–H···pi (Phe330) 2.33
pi···pi (Phe331) 5.30 pi···pi (Phe331) 5.43
pi···pi (Tyr334) 4.65 Alkyl···pi (Tyr334) 4.54
D1-AchE C–H···O (Asp72) 2.90 D4-AChE pi···pi (Trp84) 3.75
pi···pi (Trp84) 3.87, 3.98 Alkyl···pi (Phe330) 4.92
pi···pi (Trp279) 4.41, 5.66 Alkyl···pi (Phe331) 5.20




D2- AchE C–H···O (Asp72) 2.70 D5-AChE C–H···O (Asp72) 2.74
pi···pi (Trp84) 3.89, 4.00 pi···pi (Trp84) 3.93, 4.17
pi···pi (Trp279) 4.35, 5.60 F···H–C, F···C (Gly117) 2.63, 3.17
C–H···O (Ser286) 3.00 F···H–O (Tyr130) 2.93
O···H–N (Phe288) 2.71 F···O (Glu199) 2.86, 2.91
C–H···pi (Phe330) 2.40 pi···pi (Trp279) 4.10
pi···pi (Phe331) 5.29 C–H···O (Ser286) 2.74
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gorge. Replacing Trp84 by alanine significantly reduced the catalytic activity of human 
AChE (Ordentlichs et al. 1993). In the same work, Kryger et al. predicted of a finger‒
shaped void, defined by Phe288, Phe290, Phe331 and Trp233, at the acyl-binding pocket. 
X-ray crystallography and photoaffinity labeling study exhibited that Trp84 and Phe330, 
known as “anionic” subsite of the active site of AChE, plays a pivotal role in ligand 
Fig. 3 Non-covalent interaction maps of a D (Chair)-AChE, b D1 (Chair)-AChE and c D5 (Chair)-AChE  
complexes
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binding. Moreover, residue Trp279, part of peripheral anionic site located in the top of 
the gorge, also stabilizes the ligand (Farrokhnia and Nabipour 2014). The only interac-
tion site was observed at the Phe288 residue with the O…H‒N bond distance being 2.84 
Å. F substituted ligand D1, on the other hand, was found to generate multiple hydrogen 
bonding with Tyr70, Ser286 and Phe288 as shown in Fig.  3b. Both Tyr70 and Ser286 
were involved in forming C‒H…O interaction with the C atoms of the two –OCH3 
groups, however, that was not observed at the same sites of parent drug D. The bond 
lengths of the two contacts, 2.70 and 2.90 Å respectively, showed that the C‒H…O inter-
actions were moderately strong. The C‒H…pi stacking contact involving the piperidine 
ring of D1 and Phe330 became slightly more intact, as the bond length reduced to 2.40 
Å compared to that in the D-AChE complex. In terms of bond-lengths, T shaped pi‒pi 
stacking contacts at Phe331 and Tyr334 did not show any significant variation from that 
of the D-AChE system. Here it is worth noting that Kryger et al. predicted of a finger‒
shaped void, defined by Phe288, Phe290, Phe331 and Trp233, at the acyl-binding pocket 
and our computation hinted that the ligands actually approach the void by generating 
non‒covalent interactions with some of the amino acids surrounding the pocket. Like 
the parent drug, D1 showed stacking interactions with the indole fragment of Trp84. It 
is interesting to note that F did not take part in any contact with the amino acid residues 
but, as one could see, its inclusion influenced the spatial arrangement of the drug, bind-
ing affinities, introduction to new contact sites and nature of non‒bonding contacts.
The binding affinities of the Cl, Br and I substituted ligands (D2-D4) were lower com-
pared to that of D1, which could be attributed to the comparatively lesser electronegativ-
ity and larger van der Walls Radii of Cl, Br and I than that of F. In terms of the electronic 
and thermodynamic properties of the ligands, as listed in Table 1, non-bonding interac-
tion maps for these three molecules were given in Additional file 1: Figure S2. Ligand 
D2 had more favorability albeit it’s binding affinity to AChE being slight lower than that 
of D1. Contacts with the amino acid residues remained almost same to the former two 
ligands except an additional C‒H…O interaction at Asp72. The C–H…pi bond‒length at 
Phe330 became 2.35 Å, which further reduced when Cl was substituted by Br in ligand 
D3. Contacts at Trp279, Phe331 and Tyr334 did not see any abrupt change in both D2 
and D3. Potential energy surface of the iodine‒substituted ligand D4 showed the elec-
tron density be slightly positive over I. Moreover, D4 possessed lower dipole‒moment 
and was less soft than the other molecules (Table  2). This might have determined its 
low binding affinity, which was −10.2 Kcalmol−1. The value, for instance, was about 1.5 
Kcalmol−1 more positive than its fluorinated counterpart D1. D4 formed a pi‒pi stacking 
interaction (4.92 Å) with Phe330 instead of forming a C‒H…pi interaction. The number 
of total interactions that D4 formed with AChE was significantly less than that of the 
previous ligands. D4 also did not approach any amino acid at the void of the acyl-binding 
pocket. Moreover, no hydrogen-bonded residual site involving D4 was found to exist.
In ligand D5, trifluoromethyl (–CF3) group was incorporated to C37. –CF3 has been 
introduced to different organic molecules for applications in agrochemical, dyes and pig-
ments, pharmaceuticals, polymers, and material chemistry (Furuya et  al. 2011; Ji et  al. 
2011; Roy et al. 2011). Due to strong electronegativity and lipophilic nature, the applica-
tion of trifluoromethyl group in drug design can promote selective functionality related 
to physiochemical, biological and pharmacological properties (Lishchynskyi et al. 2013). 
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Incorporating –CF3 group in C37 position significantly influenced the structure of done-
pezil. –CF3 group significantly increased the dipole moment (5.857 Debye) and enhanced 
the polar nature of D5. In the D5-AChE docked structure, non-bonded interactions were 
diverse. The interaction with the swinging Phe330 was a pi‒pi stacking with a bond-dis-
tance 4.92 Å. D5 also formed non‒bonded interactions with Asp72, Trp279, Ser286, 
Phe288, Phe331 and Tyr334 which means that it had covered most of the possible voids 
and pockets where the ligand could be situated in. The nature of those interactions was 
mostly hydrophobic. Details about the types of interactions and bond‒distances are given 
in Table 4 and Fig. 3c. The most notable fact here is, however, that the three F atoms of 
the –CF3 group in benzyl ring interacted with amino acids to form strong halogen interac-
tions. F atoms held Gly117, Tyr130 and Glu199 at multiple binding sites resulting in the 
presence of O…F, C‒H…F and O‒H…F interactions. The residues were near the part known 
as “oxyanion hole” formed by the peptide NH moieties of Gly118, Gly119 and Ala201 and 
having an essential role in catalysis (Tormos et al. 2010). These non‒covalent interactions 
were from moderately strong to fairly strong with the bond distance being ranging from 
2.65 to 3.24 Å. The abundance of non‒bonding contact sites might explain the fact that 
binding affinity for D5-AChE had come highest among the ligand–receptor systems con-
sidered for the present work (−12.0 KCalmol−1). Figure 4 shows that D, D1 and D5 super-
impose well on the experimental crystal structure of E2020/AChE resolved by Kryger et al.
Interaction and binding affinity of the ligands in boat form (Dʹ–Dʹ5) against AChE
The boat forms of donepezil and the modified derivatives were due to the change of con-
formations from chair to boat at the piperidine ring. Additional file 1: Table S1 describes 
the thermodynamic and electronic properties of the boat conformers Dʹ–Dʹ5. Free ener-
gies of the boat molecules were slightly more negative compared to the chair coun-
terparts. The dipole moments and softness values for the boat conformers had larger 
values than the corresponding chair conformers. For instance, dipole moment and soft-
ness values of the boat conformer of donepezil were 3.57 and 12.16 D respectively which 
are almost 1.0 and 0.40 D units larger than that of chair donepezil. The pattern of the 
changes of the electrical and thermodynamic parameters for the Dʹ–Dʹ5 were identical to 
the D–D5 counterparts, which was demonstrated by the increasing dipole moment and 
softness up to Dʹ4 and a decrease for –CF3 modified Dʹ5. The most notable part regarding 
the boat conformers was that binding affinity for each of the molecules was 0.2‒1.0 Kcal-
mol−1 more negative compared to the counterpart chair conformers. The most favora-
ble boat ligands according to molecular docking were fluorinated and –CF3 modified 
Dʹ1 and Dʹ5 forms with binding energies being −12.6 and −12.5 Kcalmol−1 respectively. 
Comparison among the energy values has been shown in Table 3. Such binding affinity, 
however, was in less concordance when correlated with the non-covalent interactions 
found for (Dʹ–Dʹ5)-AChE complexes. According to the binding site analysis, Donepezil 
at the boat conformer was found to form a few hydrophobic contacts and C‒H…O bond-
ing with Trp279, Arg289 and His440. The latter two amino acids were not involved at 
the contact sites involving any of the chair conformers and His440 is one of the three 
amino acids of the catalytic-triad. Analysis of Dʹ1, on the other hand, saw the forma-
tion of pi‒stacking interactions with Trp84, Tyr334 and Gly335. The C‒H…pi bond dis-
tance at Tyr334 was found to be 2.70 Å. Ligand Dʹ5, on the other hand, showed stacking 
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interactions with Trp84, Phe330, Phe331 and Tyr334; moreover, the F atoms formed a 
number of H‒bonds with Trp84 and Gly118. Details about the nature of the contact sites 
for the boat conformers Dʹ, Dʹ1 and Dʹ5 against AChE are given in Additional file 1: Fig-
ure S3. Dʹ2–Dʹ4 showed some identical binding sites to that of their chair counterparts- 
stacking interactions with Trp279, Phe330 and Tyr334 for example. In addition to that, 
some hydrophobic contacts and H‒bonding at Trp8, Tyr121 and Asp285 were observed.
Pharmacokinetic parameters of the chair conformers
Our ADME (absorption, distribution, metabolism, and excretion) evaluation shows that 
all the chair forms of the drugs are non‒carcinogenic having a class III acute oral toxicity 
shown in Table 5. LD50 values for the molecules are above 2.8378 mol/Kg; trifluorome-
thyl substituted D5 has the highest LD50 value within the class (3.0139 mol/Kg) indicating 
D5 to be the best modified ligand for in vivo studies. As the human intestinal absorption 
values were found positive for all the ligands and all of the ligands are P‒glycoprotein 
inhibitor, it can inferred that the drugs will act positive in terms of bioavailability, drug 
metabolism and intestinal absorption (Broccatelli et al. 2011; Shen et al. 2010). This can be 
further reinforced by the fact that donepezil and the modified derivatives shows positivity 
towards blood brain barrier (BBB) predicting the fact that all of them are supposed to go 
through BBB. One disadvantage found for donepezil is that it shows strong hERG inhibi-
tory properties, which is responsible for adverse drug–drug interactions and cardiac side-
effects (Hundae et al. 2014). The modified molecules are, however, found to be weak hERG 
inhibitor.
Inhibition constant for the drugs have been calculated using concept of equilibrium 
between enzyme and its inhibitor
(E =  Enzyme and I =  Inhibitor; the reference concentrations for all the entities have 
been considered 1 molL−1 for the calculations) and the relationship-
where ln Kb = −ΔG/RT and ΔG = free energy of binding and are presented in the last 
row of Table 5.
E+ I↔ EI
ln Kb = − ln Ki
Fig. 4 Superposition of the chair conformers of D (green), D1 (white) and D5 (blue) on the E2020 (red)/AChE 
crystal structure resolved at 2.5 Å
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Conclusion
Our study demonstrated the binding interactions of halogenated donepezil ligands in 
chair form with AChE. Overall, halogenation increased the dipole moment of the modi-
fied ligands thereby enhancing their polar nature. Moreover, halogenation made the 
modified ligands thermodynamically more stable as evident from enthalpy and Gibbs 
free energies. The HOMO‒LUMO energy gaps of these modified ligands were reason-
ably lower than donepezil, which indicated that these compounds are more chemically 
reactive. The –CF3 modified ligand D5, however, showed some degree of anomaly from 
the pattern observed; however, its binding affinity to AChE was mostly favorable. The 
study also indicated that Br and I directed modifications did not provide performances 
as the F and –CF3 directed modifications did. Non‒covalent interactions such as pi‒pi 
stacked, pi‒pi T‒shaped, amide‒pi stacked and pi‒alkyl alongside C‒H…O and N‒H…O 
interactions were the main driving force of the enhanced performance of D1 and D5. 
The C‒H…pi interaction at Phe330 residue for D‒D3 showed strong interactions with 
the bond distances being ranged between 2.35‒2.47 Å. The boat conformers showed 
increased binding affinity than the chair conformers despite the fact that binding sites 
for the boat ligands were not entirely similar to the chair counterparts.
Additional file
Additional file 1: Figures S1–S3 depict binding pockets and non-bonding interactions. Table S1 shows the elec-
tronic and thermodynamics properties of the boat conformer of donepezil and Table S2 presents the rigid docking 
binding energy for the chair conformer of donepezil.
Table 5 Selected pharmacokinetic parameters of  Donepezil (Chair Form) and  its deriva-
tives
Probability values related to each of the parameters are given in the parenthesis
Parameters Donepezil D1 D2 D3 D4 D5
Blood Brain 
Barrier










































3.0123 2.8808 2.8378 2.8435 2.8480 3.0139
Ki (at 298 K, 
nM)
7.442 2.705 3.789 6.285 33.955 1.631
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